<DOC>
	<DOC>NCT01186445</DOC>
	<brief_summary>The purpose of this study is to determine whether intracoronary injection of morphine chlorhydrate is effective to limit ischemia-reperfusion lesion during percutaneous coronary angioplasty in patients with acute myocardial infarction (AMI).</brief_summary>
	<brief_title>Morphine In Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<criteria>1. Acute Myocardial Infarction less than 6 hours defined by 1. prolonged chest pain (&gt;15 min) 2. in association with ST elevation 1mm or more in two contiguous leads or occurence of Q wave in three contiguous leads or occurence of left bundle branch block 2. Culprit lesion eligible for percutaneous coronary intervention (PCI) 3. TIMI flow 0 before PCI 1. Fibrinolysis 2. Allergy to morphine 3. Active epilepsy 4. Brain injury or intracranial hypertension 5. Previous AMI, coronary artery bypass graft (CABG) 6. Cardiac arrest 7. Cardiogenic shock, significant mitral regurgitation or intraventricular communication at inclusion 8. Mechanical ventilation at inclusion 9. Significant ventricular arrhythmia or atrioventricular block type II or III at inclusion 10. Decompensated chronic obstructive pulmonary disease at inclusion 11. chronic hepatocellular failure 12. MRI contraindications 13. Gadolinium chelates injection contraindications 14. Current treatment with morphine chlorhydrate, buprenorphine, nalbuphine, pentazocine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>Cardioprotective effect</keyword>
	<keyword>Pharmacological postconditioning</keyword>
	<keyword>Morphine Chlorhydrate</keyword>
	<keyword>Cardiac MRI</keyword>
</DOC>